Dupilumab impact on skin resident memory T cells - DupiTrem

ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC)0 sites20 target enrollmentMarch 14, 2019

Overview

No summary available.

Registry

who.int

Start Date

March 14, 2019

End Date

TBD

Last Updated

7 years ago

Study Type

Interventional clinical trial of medicinal product

Sponsor

ARCI (trade name LYON RECHERCHE CLINIQUE : LyREC)

•Subject over 18 years of age
•For woman with childbearing potential ;
•Use of a highly effective method of birth control from at least 1 month prior to study enrollment until the last visit
•Negative urine pregnancy test at inclusion visit
•Subject diagnosed with moderate\-to\-severe AD, defined as SCORAD\=20 and/or EASI\=7 (Eichenfield et al., 2014\)
•Subject with I, II, III or IV skin phototype (according to Fitzpatrick scale)
•Subject accepting skin prick\-tests and skin biopsies
•Subject having a least one non lesional area on the body (off head and neck, feet and hands)
•Subject eligible for systemic treatment
•Failure, intolerance or contraindication to available systemic treatments (i.e. cyclosporine/ methotrexate)

•Pregnancy or breast\-feeding women, or planning to become pregnant or breastfeed during the study
•Subject currently experiencing or having a history of other concomitant skin conditions that would interfere with evaluation of AD
•History of allergic reaction to local anesthetic product
•History of wound healing disorders (e.g. hypertrophic scars, keloids)
•Subject with known active infection to HBV, HCV or HIV
•Subject with known blood dyscrasia
•Subject having an allergen immunotherapy within 3 months before study
•Subject treated by antihistamine 5 days before study. Please note, antihistamine administered to treat allergic rhino conjunctivitis is allowed after V1\.
•Subject treated with an investigational drug within 8 weeks or within 5 half\-life (if known), whichever is longer, before the baseline visit
•Subject treated with cyclosporine, methotrexate oral corticosteroids, azathioprine, mycophenolate\-mofetil, and/or any other systemic immunosupperessor/immunomodulator within 4 weeks before the study